Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Change in Cash: 2020-2024

Historic Change in Cash for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to $438.1 million.

  • NewAmsterdam Pharma Co N.V's Change in Cash fell 94.67% to -$24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.1 million, marking a year-over-year increase of 133.22%. This contributed to the annual value of $438.1 million for FY2024, which is 431.06% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Change in Cash stood at $438.1 million for FY2024, which was up 431.06% from -$132.3 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's Change in Cash's 5-year high stood at $438.1 million during FY2024, with a 5-year trough of -$132.3 million in FY2023.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Change in Cash had a median value of $402.3 million in 2022 and averaged $236.0 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Change in Cash skyrocketed by 805.34% in 2021 and then slumped by 132.89% in 2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Change in Cash (Yearly) stood at $6.1 million in 2020, then spiked by 805.34% to $55.2 million in 2021, then spiked by 629.32% to $402.3 million in 2022, then tumbled by 132.89% to -$132.3 million in 2023, then spiked by 431.06% to $438.1 million in 2024.